Incyte EPS - Earnings per Share 2010-2024 | INCY

Incyte earnings per share (EPS) for the twelve months ending September 30, 2024 was $0.14, a 92.59% decline year-over-year.

  • Incyte EPS for the quarter ending September 30, 2024 was $0.54, a 28.95% decline year-over-year.
  • Incyte 2023 annual EPS was $2.65, a 74.34% increase from 2022.
  • Incyte 2022 annual EPS was $1.52, a 64.4% decline from 2021.
  • Incyte 2021 annual EPS was $4.27, a 413.97% decline from 2020.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.

Incyte EPS - Earnings per Share 2010-2024 | INCY

  • Incyte EPS for the quarter ending September 30, 2024 was $0.54, a 28.95% decline year-over-year.
  • Incyte 2023 annual EPS was $2.65, a 74.34% increase from 2022.
  • Incyte 2022 annual EPS was $1.52, a 64.4% decline from 2021.
  • Incyte 2021 annual EPS was $4.27, a 413.97% decline from 2020.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$160.6B
Vertex Pharmaceuticals (VRTX)$126.2B
Bristol Myers Squibb (BMY)$119.7B
Gilead Sciences (GILD)$117.5B
Regeneron Pharmaceuticals (REGN)$90.2B
CSL (CSLLY)$90B
GSK (GSK)$73.6B
Argenex SE (ARGX)$35.5B
Alnylam Pharmaceuticals (ALNY)$34.7B
BioNTech SE (BNTX)$25.5B
Biogen (BIIB)$24.5B
Illumina (ILMN)$23.4B
BeiGene (BGNE)$18.9B
Moderna (MRNA)$16.7B
Genmab (GMAB)$14.9B
BioMarin Pharmaceutical (BMRN)$12.6B
Insmed (INSM)$12.5B
Vaxcyte (PCVX)$12.4B
Bio-Techne Corp (TECH)$11.8B
Sarepta Therapeutics (SRPT)$10.9B
Exelixis (EXEL)$10.2B
Revolution Medicines (RVMD)$10B
QIAGEN (QGEN)$9.9B
Intra-Cellular Therapies (ITCI)$9.4B
Bio-Rad Laboratories (BIO.B)$9.4B
Exact Sciences (EXAS)$9.3B
Roivant Sciences (ROIV)$8.6B
Repligen (RGEN)$8.3B
Ascendis Pharma (ASND)$7.7B
Halozyme Therapeutics (HALO)$7.6B